Key terms
About PAVM
PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: Medical Devices, Diagnostics, Digital Health, and Emerging Innovations. The company's products include cell collection devices, esophageal DNA tests, carpal tunnel release, implantable intraosseous vascular access devices, and antimicrobial resorbable ear tubes. PAVmed was founded on June 26, 2014 and is headquartered in New York, NY.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest PAVM news
Yesterday
8:10am ET
Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO) and PAVmed (PAVM)
May 15
3:40pm ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: HUTCHMED (HCM) and PAVmed (PAVM)
May 15
9:05am ET
PAVmed (PAVM) Receives a Buy from Lake Street
May 14
10:52am ET
PAVmed Inc Provides Informal Financial Performance Update
May 09
7:52am ET
Lucid SOS esophageal cell collection device subject to Class II FDA recall
May 01
6:23am ET
PAVmed Partners with Cancer Center to Advance Care
Apr 15
5:16am ET
Buy Rating Affirmed for PAVmed on Growth and Valuation Prospects Amidst Product Commercialization
Mar 29
7:46am ET
Buy Rating Affirmed for PAVmed with Strategic Focus on Lucid Diagnostics and Veris Cancer Care Amid Adjusted Price Target
Mar 28
9:20am ET
Analysts Offer Insights on Healthcare Companies: PAVmed (PAVM) and Simulations Plus (SLP)
Mar 28
9:02am ET
PAVmed price target lowered to $4 at Lake Street
Mar 26
7:53pm ET
PAVmed reports Q4 EPS ($1.33), two estimates ($1.79)
Mar 21
9:37am ET
Lucid Diagnostics announces data from clinical validation study of EsoGuardPAVmed
Feb 16
6:14am ET
PAVmed Inc. Distributes Lucid Stock and Adjusts Warrant Terms
No recent press releases are available for PAVM
PAVM Financials
Key terms
Ad Feedback
PAVM Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
PAVM Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range